Novartis Shares Slump 13% on Failed Clinical Trial, Amgen Drops 9%
Novartis shares plummeted 13% following a failed clinical trial for del-desiran, while Amgen shares dropped 9% on contagion fears, pressuring the Dow…
Novartis shares plummeted 13% following a failed clinical trial for del-desiran, while Amgen shares dropped 9% on contagion fears, pressuring the Dow…
Novartis shares fell 12.57% following two major clinical trial disappointments, triggering a broader sell-off in biotech partners Ionis Pharmaceuticals and Royalty Pharma.
Ionis Pharmaceuticals stock hit near 52-week lows after the Phase 3 trial for its cardiovascular drug pelacarsen failed to meet primary endpoints,…